PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 22,161 Shares of Stock

Posted by Brenda Bartman on Jul 9th, 2026

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) insider Neil Gregory Almstead sold 22,161 shares of PTC Therapeutics stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $86.00, for a total transaction of $1,905,846.00. Following the completion of the transaction, the insider owned 60,299 shares of the company’s stock, valued at $5,185,714. The trade was a 26.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neil Gregory Almstead also recently made the following trade(s):

On Tuesday, July 7th, Neil Gregory Almstead sold 24,613 shares of PTC Therapeutics stock. The shares were sold at an average price of $88.89, for a total transaction of $2,187,849.57.
On Friday, June 26th, Neil Gregory Almstead sold 8,130 shares of PTC Therapeutics stock. The shares were sold at an average price of $85.26, for a total transaction of $693,163.80.
On Thursday, June 25th, Neil Gregory Almstead sold 20,960 shares of PTC Therapeutics stock. The stock was sold at an average price of $85.97, for a total transaction of $1,801,931.20.
On Wednesday, June 24th, Neil Gregory Almstead sold 5,323 shares of PTC Therapeutics stock. The shares were sold at an average price of $85.03, for a total transaction of $452,614.69.
On Monday, June 22nd, Neil Gregory Almstead sold 23,749 shares of PTC Therapeutics stock. The shares were sold at an average price of $80.90, for a total transaction of $1,921,294.10.

PTC Therapeutics Price Performance

NASDAQ:PTCT opened at $88.57 on Thursday. PTC Therapeutics, Inc. has a 1 year low of $43.17 and a 1 year high of $89.85. The stock’s fifty day moving average price is $74.77 and its two-hundred day moving average price is $72.61. The company has a market cap of $7.35 billion, a P/E ratio of -38.01, a P/E/G ratio of 4.10 and a beta of 0.53.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.42. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 22.58%.The company had revenue of $272.55 million during the quarter, compared to analysts’ expectations of $217.42 million. During the same period in the previous year, the business earned $10.04 earnings per share. The firm’s quarterly revenue was up 43.5% compared to the same quarter last year. On average, analysts expect that PTC Therapeutics, Inc. will post 0.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PTCT has been the subject of a number of recent analyst reports. Morgan Stanley reaffirmed an “overweight” rating and set a $94.00 target price on shares of PTC Therapeutics in a report on Friday, May 8th. Raymond James Financial assumed coverage on shares of PTC Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $108.00 price objective for the company. TD Cowen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating and boosted their price objective for the company from $75.00 to $90.00 in a research note on Friday, May 8th. Wells Fargo & Company upped their target price on shares of PTC Therapeutics from $86.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, Citigroup upgraded shares of PTC Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $75.00 to $108.00 in a research note on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $91.57.

Check Out Our Latest Research Report on PTC Therapeutics

Hedge Funds Weigh In On PTC Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Empowered Funds LLC purchased a new stake in shares of PTC Therapeutics in the 1st quarter valued at about $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of PTC Therapeutics by 11.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock worth $9,109,000 after purchasing an additional 18,504 shares in the last quarter. Quantbot Technologies LP grew its holdings in shares of PTC Therapeutics by 280.1% during the second quarter. Quantbot Technologies LP now owns 2,478 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 1,826 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in shares of PTC Therapeutics in the second quarter worth approximately $1,661,000. Finally, EverSource Wealth Advisors LLC increased its position in shares of PTC Therapeutics by 247.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 814 shares during the last quarter.

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.